Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks nasal IVIG for long COVID in Immune-Weakened patients

NCT ID NCT06992401

Knowledge-focused Sponsor: Tamara C Tamas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how intranasal IVIG (a treatment given through the nose) might help people with Long COVID who also have a weak immune system. Researchers will collect health data from 50 participants, but no treatment is given as part of the study. The goal is to see if this approach can reduce symptoms like fatigue, brain fog, and inflammation. All treatment decisions are made by each clinic independently.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study enrolls adults aged 18 to 65 with persistent Long COVID symptoms and confirmed immunodeficiency, including low IgG/IgA or poor vaccine response. Participants must have elevated inflammatory markers and be free of active infections or neurological conditions. The population is observed while undergoing intranasal IVIG therapy internationally, with a focus on immunological, genetic, and quality of life outcomes.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 65 years * Clinical diagnosis of Long COVID (symptoms persisting ≥12 weeks after SARS-CoV-2 infection) * Laboratory-confirmed immunodeficiency, including one or more of the following: * Low serum IgG and/or IgA * Specific antibody deficiency * Low pneumonia titers * Elevated inflammatory markers (e.g., CRP, cytokines) * No active infections at the time of enrollment (bacterial, viral, or fungal) * Negative for Lyme disease and NMDAR antibodies * Willingness to provide informed consent for data collection and use Exclusion Criteria: * Current or recent active infection (e.g., viral, bacterial, or fungal) * Use of immunosuppressive therapy within the last 3 months * Active infections: Participants with active infections, including viral, bacterial, or fungal infections, will be excluded * Neurological disorders: Participants with diagnosed neurological disorders (e.g., multiple sclerosis, Parkinson's disease, Alzheimer's disease) will be excluded * Immunosuppressive therapy: Participants receiving immunosuppressive therapy will be excluded * Inability to comply with study assessments or procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID 19 associated coagulopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disseminated intravascular coagulation immunodeficiency disease long COVID-19 Mental Fatigue

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID 19 associated coagulopathy COVID-19 vaccination Long COVID Long COVID fatigue Long COVID syndrome Post acute sequelae of SARS CoV 2 infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.